摘要
Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications,such as variceal bleeding,ascites or hepatic encephalopathy.As such,clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis.At present,non-selective bblockers,vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia.In contrast,safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue.In recent years,several preclinical and clinical trials have focused on this latter component and other therapeutic avenues.In this review,we highlight novel data in this context and address potentially interesting therapeutic options for the future.
门脉高压症多见于肝硬化患者,是静脉曲张出血、腹水、肝性脑病等并发症的主要推动因素。门脉高压症本身可以作为肝脏失代偿的先兆,显著影响肝硬化患者的预后。目前,非选择性β受体阻滞剂(NSBBs)、血管加压素类似物、生长抑素类似物是主要治疗药物,但这些治疗方案仅仅是针对内脏器官的充血,其疗效远无法令人满意。而旨在减少肝硬化患者肝内血流阻力的安全有效的治疗方案仍不明确。近年来,一些体外研究、动物实验及临床试验聚焦于减少肝内血流阻力及其他治疗途径。本文中,我们重点探讨了这些新的治疗策略的安全性和有效性,并展望了一些具有潜在应用前景的治疗方法。
